ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP2-16 HEDIS Season Is Here
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 07, 2016
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 3041 - 3050 လၢ 4030 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP31-17 New Pre-Authorization Form for Infliximab
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 05, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP37-16 Difference in Operating Systems Identified - GY Modifier
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဒံၣ်စဲဘၢၣ် 09, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP17-16 Claims with Attachments
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 26, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP100-18 Pharmacy Benefit Exclusion for Crinone (progesterone) Gel, Finacea (alzelaic acid) Foam, Glatopa (glatiramer acetate) Injection
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 28, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP1-18 Transition of Care Management Features for New Medicare Advantage Prescription Drug Plans
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 08, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP11-16 New BlueRide Email Notification Option for SNF
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 04, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP44-17 New Pre-Authorization Form for Botulinum Toxin for Commercial Products
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဒံၣ်စဲဘၢၣ် 05, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP12-17 Prior Authorization/Pre-Approval Forms Specific to Select Medical Policies
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 31, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP32-16 Centurion Contracts with BlueLink TPA for Claims Administration Servicesa
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 18, 2016